Switch to:
Also traded in: Germany, Sweden, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 2.05
OTCPK:SWTUY's Cash-to-Debt is ranked lower than
52% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.32 vs. OTCPK:SWTUY: 2.05 )
Ranked among companies with meaningful Cash-to-Debt only.
OTCPK:SWTUY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.88 Max: No Debt
Current: 2.05
Equity-to-Asset 0.54
OTCPK:SWTUY's Equity-to-Asset is ranked lower than
60% of the 216 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. OTCPK:SWTUY: 0.54 )
Ranked among companies with meaningful Equity-to-Asset only.
OTCPK:SWTUY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.71 Max: 0.77
Current: 0.54
0.48
0.77
Interest Coverage 67.14
OTCPK:SWTUY's Interest Coverage is ranked higher than
50% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.14 vs. OTCPK:SWTUY: 67.14 )
Ranked among companies with meaningful Interest Coverage only.
OTCPK:SWTUY' s Interest Coverage Range Over the Past 10 Years
Min: 0.79  Med: 1.92 Max: 67.14
Current: 67.14
0.79
67.14
Piotroski F-Score: 6
Altman Z-Score: 5.67
Beneish M-Score: -1.77
WACC vs ROIC
9.15%
15.40%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 18.90
OTCPK:SWTUY's Operating Margin % is ranked higher than
89% of the 221 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. OTCPK:SWTUY: 18.90 )
Ranked among companies with meaningful Operating Margin % only.
OTCPK:SWTUY' s Operating Margin % Range Over the Past 10 Years
Min: -33.86  Med: -1.69 Max: 21.77
Current: 18.9
-33.86
21.77
Net Margin % 13.20
OTCPK:SWTUY's Net Margin % is ranked higher than
87% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.48 vs. OTCPK:SWTUY: 13.20 )
Ranked among companies with meaningful Net Margin % only.
OTCPK:SWTUY' s Net Margin % Range Over the Past 10 Years
Min: -29.4  Med: -1.67 Max: 15.55
Current: 13.2
-29.4
15.55
ROE % 13.23
OTCPK:SWTUY's ROE % is ranked higher than
74% of the 214 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. OTCPK:SWTUY: 13.23 )
Ranked among companies with meaningful ROE % only.
OTCPK:SWTUY' s ROE % Range Over the Past 10 Years
Min: -24.5  Med: -0.78 Max: 16.16
Current: 13.23
-24.5
16.16
ROA % 7.29
OTCPK:SWTUY's ROA % is ranked higher than
80% of the 237 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.39 vs. OTCPK:SWTUY: 7.29 )
Ranked among companies with meaningful ROA % only.
OTCPK:SWTUY' s ROA % Range Over the Past 10 Years
Min: -14.82  Med: -0.6 Max: 8.85
Current: 7.29
-14.82
8.85
ROC (Joel Greenblatt) % 237.05
OTCPK:SWTUY's ROC (Joel Greenblatt) % is ranked higher than
97% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.64 vs. OTCPK:SWTUY: 237.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OTCPK:SWTUY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -59.86  Med: -4.1 Max: 315.79
Current: 237.05
-59.86
315.79
3-Year Revenue Growth Rate 33.10
OTCPK:SWTUY's 3-Year Revenue Growth Rate is ranked higher than
91% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. OTCPK:SWTUY: 33.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OTCPK:SWTUY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -31.7  Med: -5.9 Max: 33.1
Current: 33.1
-31.7
33.1
3-Year EBITDA Growth Rate 85.70
OTCPK:SWTUY's 3-Year EBITDA Growth Rate is ranked higher than
97% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.60 vs. OTCPK:SWTUY: 85.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OTCPK:SWTUY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -41.3  Med: 10.1 Max: 85.7
Current: 85.7
-41.3
85.7
GuruFocus has detected 2 Warning Signs with Swedish Orphan Biovitrum AB $OTCPK:SWTUY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OTCPK:SWTUY's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research  
Compare:OSTO:SECT B, OSTO:CEVI, OSTO:IMMNOV, OSTO:BOUL, OSTO:CRAD B, OSL:COV, OSTO:SCIB, OSTO:ADDV A, OSTO:ADDV B, XSAT:IDL B » details
Traded in other countries:B6E.Germany, SOBI.Sweden, 0MTD.UK,
Headquarter Location:Sweden
Swedish Orphan Biovitrum AB is an integrated biotechnology company dedicated to rare diseases. Its research and product portfolio is focused on haemophilia, inflammation and genetic and metabolic diseases.

Swedish Orphan Biovitrum AB.

Ratios

vs
industry
vs
history
PE Ratio 54.05
SWTUY's PE Ratio is ranked lower than
77% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.35 vs. SWTUY: 54.05 )
Ranked among companies with meaningful PE Ratio only.
SWTUY' s PE Ratio Range Over the Past 10 Years
Min: 21.76  Med: 116.61 Max: 9217.5
Current: 54.05
21.76
9217.5
Forward PE Ratio 34.13
SWTUY's Forward PE Ratio is ranked lower than
71% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.63 vs. SWTUY: 34.13 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 54.05
SWTUY's PE Ratio without NRI is ranked lower than
76% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.61 vs. SWTUY: 54.05 )
Ranked among companies with meaningful PE Ratio without NRI only.
SWTUY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 21.76  Med: 116.37 Max: 99999999.99
Current: 54.05
21.76
99999999.99
Price-to-Owner-Earnings 59.20
SWTUY's Price-to-Owner-Earnings is ranked lower than
75% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.37 vs. SWTUY: 59.20 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
SWTUY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 26.11  Med: 55.19 Max: 1236.84
Current: 59.2
26.11
1236.84
PB Ratio 6.76
SWTUY's PB Ratio is ranked lower than
75% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.75 vs. SWTUY: 6.76 )
Ranked among companies with meaningful PB Ratio only.
SWTUY' s PB Ratio Range Over the Past 10 Years
Min: 0.71  Med: 4.65 Max: 8.06
Current: 6.76
0.71
8.06
PS Ratio 7.10
SWTUY's PS Ratio is ranked lower than
69% of the 214 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.61 vs. SWTUY: 7.10 )
Ranked among companies with meaningful PS Ratio only.
SWTUY' s PS Ratio Range Over the Past 10 Years
Min: 1.19  Med: 5.39 Max: 12.78
Current: 7.1
1.19
12.78
Price-to-Free-Cash-Flow 185.63
SWTUY's Price-to-Free-Cash-Flow is ranked lower than
94% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.66 vs. SWTUY: 185.63 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
SWTUY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.61  Med: 114.53 Max: 734.38
Current: 185.63
12.61
734.38
Price-to-Operating-Cash-Flow 87.72
SWTUY's Price-to-Operating-Cash-Flow is ranked lower than
97% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.27 vs. SWTUY: 87.72 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
SWTUY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.39  Med: 57.95 Max: 2412.5
Current: 87.72
11.39
2412.5
EV-to-EBIT 37.23
SWTUY's EV-to-EBIT is ranked lower than
66% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.02 vs. SWTUY: 37.23 )
Ranked among companies with meaningful EV-to-EBIT only.
SWTUY' s EV-to-EBIT Range Over the Past 10 Years
Min: -600.4  Med: 23.7 Max: 627.6
Current: 37.23
-600.4
627.6
EV-to-EBITDA 25.33
SWTUY's EV-to-EBITDA is ranked lower than
60% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.53 vs. SWTUY: 25.33 )
Ranked among companies with meaningful EV-to-EBITDA only.
SWTUY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -600.4  Med: 17.8 Max: 1429.9
Current: 25.33
-600.4
1429.9
Current Ratio 1.63
SWTUY's Current Ratio is ranked lower than
70% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.72 vs. SWTUY: 1.63 )
Ranked among companies with meaningful Current Ratio only.
SWTUY' s Current Ratio Range Over the Past 10 Years
Min: 1.63  Med: 2.52 Max: 3.23
Current: 1.63
1.63
3.23
Quick Ratio 1.15
SWTUY's Quick Ratio is ranked lower than
78% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. SWTUY: 1.15 )
Ranked among companies with meaningful Quick Ratio only.
SWTUY' s Quick Ratio Range Over the Past 10 Years
Min: 0.66  Med: 1.39 Max: 1.89
Current: 1.15
0.66
1.89
Days Inventory 193.27
SWTUY's Days Inventory is ranked lower than
86% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 82.10 vs. SWTUY: 193.27 )
Ranked among companies with meaningful Days Inventory only.
SWTUY' s Days Inventory Range Over the Past 10 Years
Min: 84.33  Med: 310.58 Max: 566.43
Current: 193.27
84.33
566.43
Days Sales Outstanding 60.84
SWTUY's Days Sales Outstanding is ranked lower than
51% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.14 vs. SWTUY: 60.84 )
Ranked among companies with meaningful Days Sales Outstanding only.
SWTUY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 29.61  Med: 56.53 Max: 73.93
Current: 60.84
29.61
73.93
Days Payable 64.20
SWTUY's Days Payable is ranked higher than
58% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 58.94 vs. SWTUY: 64.20 )
Ranked among companies with meaningful Days Payable only.
SWTUY' s Days Payable Range Over the Past 10 Years
Min: 43.2  Med: 89.54 Max: 198.48
Current: 64.2
43.2
198.48

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.40
SWTUY's 3-Year Average Share Buyback Ratio is ranked higher than
77% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. SWTUY: -0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SWTUY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -68.1  Med: -14 Max: 21.4
Current: -0.4
-68.1
21.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 5.30
SWTUY's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
78% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.22 vs. SWTUY: 5.30 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
SWTUY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 4.45  Med: 5.85 Max: 8.57
Current: 5.3
4.45
8.57
Price-to-Median-PS-Value 1.32
SWTUY's Price-to-Median-PS-Value is ranked lower than
69% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. SWTUY: 1.32 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SWTUY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 1 Max: 2.07
Current: 1.32
0.23
2.07
Earnings Yield (Greenblatt) % 2.69
SWTUY's Earnings Yield (Greenblatt) % is ranked higher than
68% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.52 vs. SWTUY: 2.69 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SWTUY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -9.7  Med: 0.2 Max: 4.6
Current: 2.69
-9.7
4.6

More Statistics

Revenue (TTM) (Mil) $611.01
EPS (TTM) $ 0.30
Beta1.49
Short Percentage of Float0.00%
52-Week Range $10.25 - 16.49
Shares Outstanding (Mil)268.78 (ADR)

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 721 961 795
EPS ($) 0.47 0.64 0.59
EPS without NRI ($) 0.47 0.64 0.59
EPS Growth Rate
(Future 3Y To 5Y Estimate)
25.59%
Dividends per Share ($)
» More Articles for SWTUY

Headlines

Articles On GuruFocus.com
ID Watchdog Announces Special and Annual General Meeting Date and Record Date Jun 23 2017 
Ironclad Performance Wear Postpones 2017 Annual Meeting of Stockholders Jun 23 2017 
Delta and Korean Air Create Leading trans-Pacific Joint Venture Jun 23 2017 
Harwood Feffer LLP Announces Investigation of EnerNOC, Inc. Jun 23 2017 
Charles D. Christy Named Chief Financial Officer Jun 23 2017 
Harwood Feffer LLP Announces Investigation of CardConnect Corp. Jun 23 2017 
eCobalt Provides Feasibility Study Update on the Idaho Cobalt Project Jun 23 2017 
Tanger Outlet Centers Schedules Second Quarter 2017 Earnings Release and Conference Call Jun 23 2017 
Cortelco Systems Puerto Rico, Inc. Board of Directors Authorizes Dividend Jun 23 2017 
Take-Two Is Set to Soar Higher Jun 23 2017 

More From Other Websites
Sobi™ Keeps the Partner Products Business Area as an Integral Part of the Company Jun 05 2017
Sobi™ Discloses Payments to the Healthcare Professionals and Healthcare Organisations to Increase... May 31 2017
Swedish Orphan Biovitrum AB - Elocta® Approved in the Kingdom of Saudi Arabia for the Treatment of... May 18 2017
Swedish Orphan Biovitrum AB - Orfadin® Capsules Approved in the Kingdom of Saudi Arabia for the... May 17 2017
Guido Oelkers Appointed President and CEO at Sobi May 04 2017
Swedish Orphan Biovitrum AB :SWTUY-US: Earnings Analysis: Q1, 2017 By the Numbers : May 3, 2017 May 03 2017
Sobi Opens Office in Greece May 03 2017
Invitation - Presentation of Sobi's Q1 2017 Results Apr 13 2017
Swedish Orphan Biovitrum AB - FDA Approves in-use Storage at Room Temperature for Orfadin® Capsules Mar 07 2017
Sobi™ Receives Approval From the European Medicines Agency for Higher capacity Drug Substance... Mar 02 2017
Swedish Orphan Biovitrum AB :SWTUY-US: Earnings Analysis: 2016 By the Numbers : February 22, 2017 Feb 22 2017
Sobi™ Enters Into new Distribution Agreement With Valeant for Ammonul® Feb 21 2017
Swedish Orphan Biovitrum AB - Statement Regarding Speculations on a Potential Sale of the Partner... Feb 03 2017
Swedish Orphan Biovitrum AB - Invitation - Presentation of Sobi's Q4 and FY 2016 Results Feb 03 2017
Swedish Orphan Biovitrum AB - Long-term Safety and Efficacy Data of Extended Half-life Therapy... Feb 02 2017
Sobi Obtains Approval From the European Commission for new Dosing Frequency of Orfadin® Feb 02 2017
Sobi and Bioverativ to Reveal new Long-term Safety and Efficacy Data of Elocta® and Alprolix® at... Feb 01 2017
Swedish Orphan Biovitrum AB: First Patients Enrolled in 24 Month Real-world Study Evaluating... Jan 19 2017
CEO Geoffrey McDonough to Leave Sobi Jan 09 2017
Armin Reininger Joins Sobi as Senior Vice President, Head of Global Medical and Scientific Affairs Jan 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}